Ninlaro (ixazomib) — United Healthcare

Initial criteria

• Diagnosis of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
• Used in combination with Rituxan (rituximab) and dexamethasone

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Ninlaro therapy

Approval duration

12 months